Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan

for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

Abstract

Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33%). The probability of overall survival and the cumulative incidence of relapse at 3years were 24% and 59%, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Primary Myelofibrosis
Cell Transplantation
Japan
Retrospective Studies
Survival
Splenomegaly
Acute Myeloid Leukemia
Recurrence
Drug Therapy
Incidence

Keywords

  • Acute myelofibrosis
  • Acute myeloid leukemia
  • Acute myelosclerosis
  • Acute panmyelosis with myelofibrosis
  • Hematopoietic cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (Accepted/In press). Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.08.006

Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis : A Retrospective Study in Japan. / for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan. Biology of Blood and Marrow Transplantation. 2018 Jan 1. https://doi.org/10.1016/j.bbmt.2018.08.006
for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. / Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis : A Retrospective Study in Japan. In: Biology of Blood and Marrow Transplantation. 2018.
@article{87b30d2115064b2bb292e321da525265,
title = "Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan",
abstract = "Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33{\%}). The probability of overall survival and the cumulative incidence of relapse at 3years were 24{\%} and 59{\%}, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF.",
keywords = "Acute myelofibrosis, Acute myeloid leukemia, Acute myelosclerosis, Acute panmyelosis with myelofibrosis, Hematopoietic cell transplantation",
author = "{for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Takaaki Konuma and Tadakazu Kondo and Takahito Kawata and Koji Iwato and Yuji Sato and Takehiko Mori and Kazuteru Ohashi and Hideyuki Nakazawa and Hiroyuki Sugahara and Hiroatsu Ago and Tetsuya Eto and Yutaka Imamura and Takahiro Fukuda and Yoshinobu Kanda and Yoshiko Atsuta and Shingo Yano",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.08.006",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis

T2 - A Retrospective Study in Japan

AU - for the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Konuma, Takaaki

AU - Kondo, Tadakazu

AU - Kawata, Takahito

AU - Iwato, Koji

AU - Sato, Yuji

AU - Mori, Takehiko

AU - Ohashi, Kazuteru

AU - Nakazawa, Hideyuki

AU - Sugahara, Hiroyuki

AU - Ago, Hiroatsu

AU - Eto, Tetsuya

AU - Imamura, Yutaka

AU - Fukuda, Takahiro

AU - Kanda, Yoshinobu

AU - Atsuta, Yoshiko

AU - Yano, Shingo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33%). The probability of overall survival and the cumulative incidence of relapse at 3years were 24% and 59%, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF.

AB - Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33%). The probability of overall survival and the cumulative incidence of relapse at 3years were 24% and 59%, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF.

KW - Acute myelofibrosis

KW - Acute myeloid leukemia

KW - Acute myelosclerosis

KW - Acute panmyelosis with myelofibrosis

KW - Hematopoietic cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85053309440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053309440&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.08.006

DO - 10.1016/j.bbmt.2018.08.006

M3 - Article

C2 - 30103016

AN - SCOPUS:85053309440

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -